Emispheres GLP-1 safe after oral delivery

Emisphere have announced the publication of a study assessing the oral delivery of GLP-1 and PYY3-36 using Emisphere’s proprietary delivery technology. The study showed that the peptides could be delivered orally in humans with safety and efficiency.

Novo Nordisk submit new drug application for liraglutide in Japan

Novo Nordisk have submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for the approval of liraglutide, a once-daily human GLP-1 analogue, for the treatment of people with type 2 diabetes. The drug is under review in the US and EU.

Zealand Pharmaceutical’s GLP-1 Agonist AVE0010 enters Phase III trials in Patients With Type 2 Diabetes

Zealand Pharmaceutical’s GLP-1 Agonist AVE0010 enters Phase III trials in Patients With Type 2 Diabete

Emisphere publish data on Oral GLP-1

Emisphere have released Phase I data from a clinical study assessing the oral delivery of GLP-1 peptide. The delivery agent, SNAC, allowed for rapid oral absorption of GLP-1.

Emisphere and Novo Nordisk collaborate on oral GLP-1 receptor agonists

Emisphere and Novo Nordisk have entered in to an agreement to collaborate on oral GLP-1 receptor agonists for Diabetes. Emisphere’s will apply its eligen(R) technology to Novo Nordisk’s drug candidates.

Roches GLP-1 Taspoglutide moves into phase III

Data presented at the ADA meeting show that Roche and Ipsen’s GLP-1 analog taspoglutide demonstrates efficacy and is well tolerated in patients with type 2 diabetes. The drug is now moving in to Phase III trials.

Stimulation of the glucagon-like peptide 1 receptor stimulates neurogenesis

Glucagon-like peptide 1 receptor (GLP-1R) agonist Exendin-4 has been shown to stimulate neurogenesis in animal models of Parkinson’s disease